Huiyu Pharmaceutical announced that the company's self-developed HY-2003 clinical trial application was approved by the State Drug Administration. HY-2003 is a new dosage form containing deoxycholic acid. It is intended to improve moderate to severe prominent contours caused by fat accumulation under the chin in adults. Deoxycholic acid physically destroys adipocytes and triggers an inflammatory response, thereby encouraging macrophages to remove damaged fat cells and achieve the effect of dissolving localized fat. HY-2003 is a domestic product that has not yet been approved for sale.

Huiyu Pharmaceutical announced that the company's self-developed HY-2003 clinical trial application was approved by the State Drug Administration. HY-2003 is a new dosage form containing deoxycholic acid. It is intended to improve moderate to severe prominent contours caused by fat accumulation under the chin in adults. Deoxycholic acid physically destroys adipocytes and triggers an inflammatory response, thereby encouraging macrophages to remove damaged fat cells and achieve the effect of dissolving localized fat. HY-2003 is a domestic product that has not yet been approved for sale.